---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117256"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:42:50.484967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cara: $83M cash, royalty deal up to $40M, oral DFK Phase 3 readouts 2023-2026

## Summary
- Cash $83M as of Sep 30, 2023; royalty sale with HCRx for up to $40M ($37.5M expected Q4 2023).
- KORSUVA injection launched with CSL Vifor/Fresenius; approved in US, EU, Japan; TDAPA expires Mar 31, 2024.
- Oral DFK Phase 3: KIND1 AD topline Dec 2023; KICK1&2 CKD topline 2H2024; KOURAGE1 NP topline 2H2024.
- No debt, 54M shares outstanding, cash runway into 2025.

## SEC filing metadata
- accession: 0001104659-23-117256
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/0001104659-23-117256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/tm2330513d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117256
- JSON: https://secwatch.observer/filing/0001104659-23-117256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.